Weight loss jab decision unfair on region -says MSP

A DECISION not to prescribe the Mounjaro injection in this region for weight loss has been defended by NHS Dumfries and Galloway.

The health board have been criticised by Galloway and West Dumfries MSP Finlay Carson for creating a ‘postcode lottery’ and denying access to the drug which has been approved by by the Scottish Medicines Consortium (SMC).

However, health officials have pointed out the high cost of the drug, which is also used for diabetes care, as well as stressing their current financial difficulties.

A spokesperson said: “NHS Dumfries and Galloway recognises the potential benefits of Mounjaro (tirzepatide) for both type two diabetes and weight management. However, all medicines must be paid for from the single local health budget from which all NHS services in the region must be funded. Given the very significant financial pressures facing the organisation, the Board Management Team decided earlier this year not to approve its prescribing for weight loss.

“In reaching this decision, members noted not only the high cost of the drug itself but also the additional service investment required for prescribing, monitoring, and follow-up. While we continue to review the case for its use in type two diabetes, there is currently no funding to support its use for obesity.

“This approach is consistent with the position within Scotland, where Mounjaro is not generally available from the NHS for weight management.

“The position will be kept under review, and if resources become available in future the Board would reconsider whether to progress a full cost/benefit analysis.”

But Mr Carson has written to both the Health Board and the Cabinet Secretary for Health with his ‘serious concerns’.

He said: “Patients in Dumfries and Galloway should not be disadvantaged compared to those in other parts of Scotland. Tirzepatide (Mounjaro) has proven benefits in tackling obesity and improving glycaemic control—conditions that place a huge strain on rural health services.”

And he believes it could even lead to longer term savings for the NHS, pointing out that early intervention into obesity could reduce complications such as cardiovascular disease, renal failure, and diabetes-related hospital admissions.

The MSP has now asked the Health Secretary to clarify the national position on implementing approved medicines when local budgets are under pressure; consider targeted financial support to ensure equitable access everywhere; and outline steps to prevent regional disparities in access to innovative treatments.

In addition, he is concerned at reports that some constituents who have accessed tirzepatide privately are unable to obtain routine NHS support such as blood tests or clinical advice.

“This lack of oversight poses risks to patient safety and creates a gap in care for those actively trying to manage their health,” he added.